Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.

NCT03053427 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT03053427
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03053427 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome.
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
March 30, 2017
Completion date
June 25, 2018
Enrollment
375 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome (rls)